Published in Blood on July 01, 2002
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature (2010) 5.43
A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell (2007) 4.59
Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell (2009) 4.43
Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood (2011) 4.35
The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. J Exp Med (2011) 3.89
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A (2003) 3.46
NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci U S A (2011) 2.74
Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature (2014) 2.70
Pathbase: a database of mutant mouse pathology. Nucleic Acids Res (2004) 2.66
Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood (2007) 2.30
NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood (2005) 2.03
MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell (2014) 1.98
Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways. Blood (2006) 1.98
The role of the chromatin remodeler Mi-2beta in hematopoietic stem cell self-renewal and multilineage differentiation. Genes Dev (2008) 1.82
Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J (2005) 1.79
Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell (2009) 1.78
Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ (2013) 1.77
Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood (2015) 1.75
EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice. Mol Cell Biol (2007) 1.72
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature (2009) 1.72
Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet (2011) 1.71
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A (2006) 1.71
The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest (2005) 1.68
p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev (2010) 1.66
HOXB4 enforces equivalent fates of ES-cell-derived and adult hematopoietic cells. Proc Natl Acad Sci U S A (2005) 1.65
Integrating mouse anatomy and pathology ontologies into a phenotyping database: tools for data capture and training. Mamm Genome (2008) 1.62
Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell (2009) 1.61
The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. J Clin Invest (2007) 1.61
Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci U S A (2004) 1.60
Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. J Clin Invest (2011) 1.59
Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood (2008) 1.50
Negative effects of GM-CSF signaling in a murine model of t(8;21)-induced leukemia. Blood (2012) 1.42
A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. J Exp Med (2015) 1.42
Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. Blood (2015) 1.39
Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction. Blood (2009) 1.37
Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. Cancer Cell (2009) 1.36
Sox17 expression confers self-renewal potential and fetal stem cell characteristics upon adult hematopoietic progenitors. Genes Dev (2011) 1.36
A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood (2006) 1.35
A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med (2008) 1.34
Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood (2007) 1.33
Practical pathology of aging mice. Pathobiol Aging Age Relat Dis (2011) 1.32
Histopathology reveals correlative and unique phenotypes in a high-throughput mouse phenotyping screen. Dis Model Mech (2014) 1.30
Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice. J Clin Invest (2007) 1.30
Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation. Cancer Res (2007) 1.30
Cdc42 critically regulates the balance between myelopoiesis and erythropoiesis. Blood (2007) 1.28
Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. Proc Natl Acad Sci U S A (2004) 1.28
Phenotype ontologies for mouse and man: bridging the semantic gap. Dis Model Mech (2010) 1.28
Retracted Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun (2012) 1.24
Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell (2014) 1.23
The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. Blood (2009) 1.21
Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proc Natl Acad Sci U S A (2006) 1.20
Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice. Blood (2011) 1.18
Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms. J Clin Invest (2005) 1.18
Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5. J Clin Invest (2008) 1.16
Modeling the evolution of ETV6-RUNX1-induced B-cell precursor acute lymphoblastic leukemia in mice. Blood (2011) 1.16
MYC levels govern hematopoietic tumor type and latency in transgenic mice. Blood (2006) 1.16
Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med (2010) 1.15
Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med (2007) 1.13
Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo. Blood (2010) 1.13
Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood (2013) 1.12
Leukemic transformation in mice expressing a NUP98-HOXD13 transgene is accompanied by spontaneous mutations in Nras, Kras, and Cbl. Blood (2008) 1.12
Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9. Blood (2005) 1.11
Expression of a CALM-AF10 fusion gene leads to Hoxa cluster overexpression and acute leukemia in transgenic mice. Cancer Res (2007) 1.07
Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice. Blood (2011) 1.06
Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood (2014) 1.05
Identification of chromatin remodeling genes Arid4a and Arid4b as leukemia suppressor genes. J Natl Cancer Inst (2008) 1.05
A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J Exp Med (2012) 1.05
Effects of dietary antioxidant supplementation on the development of malignant lymphoma and other neoplastic lesions in mice exposed to proton or iron-ion radiation. Radiat Res (2008) 1.05
Mouse Tumor Biology (MTB): a database of mouse models for human cancer. Nucleic Acids Res (2014) 1.04
Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells. Proc Natl Acad Sci U S A (2010) 1.01
A mouse by any other name ... J Invest Dermatol (2009) 1.01
Expression of the runt homology domain of RUNX1 disrupts homeostasis of hematopoietic stem cells and induces progression to myelodysplastic syndrome. Blood (2012) 0.97
Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo. Oncogene (2008) 0.97
The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood (2006) 0.97
The histopathologic and molecular basis for the diagnosis of histiocytic sarcoma and histiocyte-associated lymphoma of mice. Vet Pathol (2010) 0.97
Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia. Blood (2010) 0.95
Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis. EMBO J (2005) 0.95
Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway. PLoS One (2011) 0.95
The ETS factor TEL2 is a hematopoietic oncoprotein. Blood (2005) 0.93
Synergistic antileukemic activity of carnosic acid-rich rosemary extract and the 19-nor Gemini vitamin D analogue in a mouse model of systemic acute myeloid leukemia. Oncology (2008) 0.93
Enforced expression of the homeobox gene Mixl1 impairs hematopoietic differentiation and results in acute myeloid leukemia. Proc Natl Acad Sci U S A (2006) 0.93
Lyn- and PLC-beta3-dependent regulation of SHP-1 phosphorylation controls Stat5 activity and myelomonocytic leukemia-like disease. Blood (2010) 0.93
Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia. Blood (2011) 0.92
OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1. Cancer Res (2005) 0.92
RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia. Blood (2008) 0.92
Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice. Blood (2009) 0.92
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood (2013) 0.92
Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETO mouse model. EMBO Mol Med (2013) 0.92
Contribution of an aged microenvironment to aging-associated myeloproliferative disease. PLoS One (2012) 0.91
Disruption of NAD(P)H:quinone oxidoreductase 1 gene in mice leads to radiation-induced myeloproliferative disease. Cancer Res (2008) 0.90
Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment. PLoS One (2009) 0.90
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia. Sci Transl Med (2015) 0.89
Acute loss of TET function results in aggressive myeloid cancer in mice. Nat Commun (2015) 0.88
MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia. Leukemia (2012) 0.88
Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13-driven mouse model. Blood (2012) 0.88
Smap1 deficiency perturbs receptor trafficking and predisposes mice to myelodysplasia. J Clin Invest (2013) 0.87
Novel insights into the pathogenesis of the Graffi murine leukemia retrovirus. J Virol (2006) 0.87
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol (2002) 20.87
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2003) 13.92
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature (2010) 13.82
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
The World Health Organization (WHO) classification of the myeloid neoplasms. Blood (2002) 10.87
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell (2011) 10.50
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
p53 mutant mice that display early ageing-associated phenotypes. Nature (2002) 10.05
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 8.74
Tenets of PTEN tumor suppression. Cell (2008) 8.61
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 7.75
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood (2011) 7.43
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
A critical role for IL-21 in regulating immunoglobulin production. Science (2002) 7.09
Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell (2011) 7.02
Does the ribosome translate cancer? Nat Rev Cancer (2003) 6.89
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64
Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 6.52
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52
Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature (2011) 6.39
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A (2008) 5.90
The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell (2005) 5.81
Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol (2007) 5.79
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature (2004) 5.61
Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet (2004) 5.55
Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci U S A (2004) 5.55
NCI Thesaurus: a semantic model integrating cancer-related clinical and molecular information. J Biomed Inform (2006) 5.46
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods (2011) 5.34
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell (2011) 5.19
PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell (2003) 5.13
A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med (2013) 4.96
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Nucleophosmin and cancer. Nat Rev Cancer (2006) 4.82
NCI Thesaurus: using science-based terminology to integrate cancer research results. Stud Health Technol Inform (2004) 4.61
Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood (2003) 4.54
Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell (2011) 4.49
Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell (2009) 4.43
Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol (2004) 4.43
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell (2002) 4.36
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med (2012) 4.26
TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol (2008) 4.21
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
Subtle variations in Pten dose determine cancer susceptibility. Nat Genet (2010) 4.19
Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A (2010) 4.17
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal (2010) 4.15
The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol (2008) 4.15
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell (2006) 4.15
New genes involved in cancer identified by retroviral tagging. Nat Genet (2002) 4.14
Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology (2003) 4.10
Role of nucleophosmin in embryonic development and tumorigenesis. Nature (2005) 4.09
Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity (2007) 4.07
Bethesda proposals for classification of lymphoid neoplasms in mice. Blood (2002) 4.07